SINOVAC BIOTECH LTD

SVA

$642M

Small Cap

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 0 past

⭐Phase 3Next

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV Phase 3 Results Expected

March 2026~Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV150

Primary completion for Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV trial (NCT07211152) in Influenza

Source

⭐Phase 3

Sinovac PCV13 Phase 3 Results Expected

May 12, 2026Sinovac PCV133,080

Primary completion for Sinovac PCV13 trial (NCT06617715) in Pneumococcal Infectious Disease

Source

Phase 2

Oral hexavalent reassortant rotavirus attenuated live vaccine Phase 2 Results Expected

Jun 15, 2026Oral hexavalent reassortant rotavirus attenuated live vaccine400

Primary completion for Oral hexavalent reassortant rotavirus attenuated live vaccine trial (NCT06967272) in Rotavirus Gastroenteritis

Source

Phase 2

Sinovac PCV24 Phase 2 Results Expected

September 2026~Sinovac PCV24420

Primary completion for Sinovac PCV24 trial (NCT07300644) in Pneumococcal Infectious Disease

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Sinovac rabies vaccine

Phase 3

Rabies (Healthy Volunteers)

investigational 23-valent PPV

Phase 3

Pneumococcal Infections

400U /0.5ml EV71 vaccine

Phase 3

Hand, Foot and Mouth Disease

Investigational sIPV

Phase 3

Poliomyelitis

three consecutive lots of EV71 vaccine

Phase 3

Hand, Foot and Mouth Disease

Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

Phase 3

Poliomyelitis

Quadrivalent influenza vaccine

Phase 3

Seasonal Influenza

Investigational tetanus vaccine, adsorbed

Phase 3

Tetanus

Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14

Phase 3

Covid19

Vaccine manufactured at commercialized scale

Phase 3

Varicella

Sinovac PCV13

Phase 3

Pneumococcal Infectious Disease

investigational live attenuated mumps vaccine

Phase 3

Mumps

control live attenuated mumps vaccine

Phase 3

Mumps

Inactivated COVID-19 Vaccine

Phase 3

COVID-19

Investigational live attenuated varicella vaccine

Phase 3

Varicella

COVID-19 Vaccine,Inactivated

Phase 3

COVID-19

Varicella Vaccine

Phase 3

Varicella

COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)

Phase 3

COVID-19

36-71 months old children-experimental EV71 vaccine.

Phase 3

Hand, Foot and Mouth Disease

sIPV-sIPV-bOPV vaccination schedule

Phase 3

Poliomyelitis

Trivalent influenza vaccine (contains B/Victoria strain)

Phase 3

Seasonal Influenza

sIPV-bOPV-bOPV vaccination schedule

Phase 3

Poliomyelitis

Quadrivalent influenza vaccine(0.5ml)

Phase 3

Seasonal Influenza

Influenza Vaccine (Split Virion), Inactivated, Quadrivalent

Phase 3

Seasonal Influenza

Experimental vaccine

Phase 3

Poliomyelitis

Quadrivalent influenza vaccine(0.25ml)

Phase 3

Seasonal Influenza

bivalent enterovirus vaccine (Vero cell), inactivated

Phase 3

Hand, Foot, and Mouth Disease（HFMD)

Sabin Strain Inactivated Poliovirus Vaccine

Phase 3

Poliomyelitis

Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV

Phase 3

Influenza

Single-dose regimen of high dosage investigational sIPV

Phase 2

Poliomyelitis

Sinovac PCV24

Phase 2

Pneumococcal Infectious Disease

low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated

Phase 2

Hand, Foot and Mouth Disease

pandemic influenza vaccine (H5N1 strain NIBRG-14)

Phase 2

Pandemic Influenza

100U EV71 vaccine with adjuvant

Phase 2

Infection, Viral, Enterovirus

Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Phase 2

COVID-19

split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)

Phase 2

Influenza

Oral hexavalent reassortant rotavirus attenuated live vaccine

Phase 2

Rotavirus Gastroenteritis

COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain

Phase 2

COVID-19

Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule

Phase 2

COVID-19

SARS-CoV-2 Inactivated Vaccine

Phase 2

COVID-19

Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

Phase 2

COVID-19

Drug Name	Phase	Indication	Designations
Sinovac rabies vaccine	Phase 3	Rabies (Healthy Volunteers)	-
investigational 23-valent PPV	Phase 3	Pneumococcal Infections	-
400U /0.5ml EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-
Investigational sIPV	Phase 3	Poliomyelitis	-
three consecutive lots of EV71 vaccine	Phase 3	Hand, Foot and Mouth Disease	-
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age	Phase 3	Poliomyelitis	-
Quadrivalent influenza vaccine	Phase 3	Seasonal Influenza	-
Investigational tetanus vaccine, adsorbed	Phase 3	Tetanus	-
Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14	Phase 3	Covid19	-
Vaccine manufactured at commercialized scale	Phase 3	Varicella	-
Sinovac PCV13	Phase 3	Pneumococcal Infectious Disease	-
investigational live attenuated mumps vaccine	Phase 3	Mumps	-
control live attenuated mumps vaccine	Phase 3	Mumps	-
Inactivated COVID-19 Vaccine	Phase 3	COVID-19	-
Investigational live attenuated varicella vaccine	Phase 3	Varicella	-
COVID-19 Vaccine,Inactivated	Phase 3	COVID-19	-
Varicella Vaccine	Phase 3	Varicella	-
COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)	Phase 3	COVID-19	-
36-71 months old children-experimental EV71 vaccine.	Phase 3	Hand, Foot and Mouth Disease	-
sIPV-sIPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-
Trivalent influenza vaccine (contains B/Victoria strain)	Phase 3	Seasonal Influenza	-
sIPV-bOPV-bOPV vaccination schedule	Phase 3	Poliomyelitis	-
Quadrivalent influenza vaccine(0.5ml)	Phase 3	Seasonal Influenza	-
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent	Phase 3	Seasonal Influenza	-
Experimental vaccine	Phase 3	Poliomyelitis	-
Quadrivalent influenza vaccine(0.25ml)	Phase 3	Seasonal Influenza	-
bivalent enterovirus vaccine (Vero cell), inactivated	Phase 3	Hand, Foot, and Mouth Disease（HFMD)	-
Sabin Strain Inactivated Poliovirus Vaccine	Phase 3	Poliomyelitis	-
Participants will receive one dose of vaccine (0.5 mL) of Sinovac QIV	Phase 3	Influenza	-
Single-dose regimen of high dosage investigational sIPV	Phase 2	Poliomyelitis	-
Sinovac PCV24	Phase 2	Pneumococcal Infectious Disease	-
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated	Phase 2	Hand, Foot and Mouth Disease	-
pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Pandemic Influenza	-
100U EV71 vaccine with adjuvant	Phase 2	Infection, Viral, Enterovirus	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)	Phase 2	Influenza	-
Oral hexavalent reassortant rotavirus attenuated live vaccine	Phase 2	Rotavirus Gastroenteritis	-
COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain	Phase 2	COVID-19	-
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule	Phase 2	COVID-19	-
SARS-CoV-2 Inactivated Vaccine	Phase 2	COVID-19	-
Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28	Phase 2	COVID-19	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

SVA News